Clinicopathological correlations in pituitary adenomas

Brain Pathology

Volumn 22, Issue 4, 2012, Pages 443-453

  Mete, Ozgur ^a,b   Asa, Sylvia L ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Corticotroph adenoma; Gonadotroph adenoma; Immunohistochemistry; Lactotroph adenoma; Pituitary adenoma; Somatotroph adenoma; Thyrotroph adenoma; Transcription factors

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; PROOPIOMELANOCORTIN; TRANSCRIPTION FACTOR CDX2;

ACTH SECRETING ADENOMA; BLOOD FLOW; CELL DIFFERENTIATION; DIAGNOSIS; ELECTRON MICROSCOPY; GENE MUTATION; GROWTH HORMONE SECRETING ADENOMA; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROLACTINOMA; RADIOLOGY; REVIEW; TUMOR VOLUME;

ADENOMA; HUMANS; PITUITARY NEOPLASMS;

EID: 84862486659     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2012.00599.x     Document Type: Review

References (66)

1. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A (1990) Clinically non-functioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336-340. (Pubitemid 20227010)
2. Al-Brahim NY, Asa SL (2006) My approach to pathology of the pituitary gland. J Clin Pathol 59:1245-1253. (Pubitemid 46055199)
3. Al-Shraim M, Asa SL (2006) The 2004World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol 111:1-7. (Pubitemid 43013820)
4. Anniko M, Tribukait B, Wersäll J (1984) DNA ploidy and cell phase in human pituitary tumors. Cancer 53:1708-1713. (Pubitemid 14127510)
5. Appel JG, Bergsneider M, Vinters H, Salamon N, Wang MB, Heaney AP (2011) Acromegaly due to an ectopic pituitary adenoma in the clivus: case report and review of literature. Pituitary DOI: 10.1007/s11102-011-0345-9.
6. Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med 132:1231-1240.
7. Asa SL (2011) Tumors of the Pituitary Gland. Fascicle 15, 4th Series. The Atlas of Tumor Pathology. Armed Forces Institute of Pathology: Washington DC.
8. Asa SL, Ezzat S (1999) Molecular determinants of pituitary cytodifferentiation. Pituitary 1:159-168.
9. Asa SL, Ezzat S (2002) Medical management of pituitary adenomas: structural and ultrastructural changes. Pituitary 5:133-139. (Pubitemid 36336018)
10. Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97-126.
11. Asa SL, Kovacs K, Tindall GT, Barrow DL, Horvath E, Vecsei P (1984) Cushing's disease associated with an intrasellar gangliocytoma producing corticotrophin-releasing factor. Ann Intern Med 101:789-793. (Pubitemid 15187370)
12. Asa SL, Scheithauer BW, Bilbao JM, Horvath E, Ryan N, Kovacs K et al (1984) A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab 58:796-803. (Pubitemid 14102099)
13. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S et al (2007) A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67:7505-7511. (Pubitemid 47206580)
14. Beck-Peccoz P, Persani L (2002) Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 5:83-88. (Pubitemid 36336013)
15. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290-6295. (Pubitemid 41606558)
16. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML et al (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95:E280-E290.
17. Colao A, Savastano S (2011) Medical treatment of prolactinomas. Nat Rev Endocrinol 7:267-278.
18. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon.
19. Erdogan N, Sarsilmaz A, Boyraz EI, Ozturkcan S (2012) Ectopic pituitary adenoma presenting as a nasopharyngeal mass: CT and MRI findings. Clin Neurol Neurosurg 114:414-416.
20. Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr (2009) Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 71:92-99.
21. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613-619. (Pubitemid 38970613)
22. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377-382.
23. Findling JW, Aron DC, Tyrrell JB Shinsako JH, Fitzgerald PA, Norman D, Wilson CB, Forsham PH (1981) Selective venous sampling for ACTH in Cushing's syndrome. Differentiation between Cushing's disease and the ectopic ACTH syndrome. Ann Intern Med 94:647-652. (Pubitemid 11112642)
24. Fitzgibbons PL, Appley AJ, Turner RR, Bishop PC, Parker JW, Breeze RE et al (1988) Flow cytometric analysis of pituitary tumors. Correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer 62:1556-1560.
25. Franscella S, Favod-Coune C-A, Pizzolato G, Asa SL, Gaillard R, Bernay J, Philippe J (1991) Pituitary corticotroph adenoma with Crooke's hyalinization. Endocr Pathol 2:111-116.
26. Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L (1995) Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 8:160-164.
27. George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, Meyer FB (2003) Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330-1336. (Pubitemid 37185824)
28. Gicquel C, LeBouc Y, Luton J-P, Girad F, Bertagna X (1992) Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab 75:472-475.
29. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S (1990) Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71:1427-1433. (Pubitemid 120032755)
30. Horvath E (1994) Ultrastructural markers in the pathologic diagnosis of pituitary adenomas. Ultrastruct Pathol 18:171-179.
31. Horvath E, Kovacs K, Singer W, Ezrin C, Kerenyi NA (1977) Acidophil stem cell adenoma of the human pituitary. Arch Pathol Lab Med 101:594-599. (Pubitemid 8230234)
32. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland. A histologic, immunocytologic, and ultrastructural study. Am J Pathol 98:617-638. (Pubitemid 10154792)
33. Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29:511-524. (Pubitemid 41769939)
34. Hsu DW, Hakim F, Biller BMK, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78:753-761. (Pubitemid 23121917)
35. Jagannathan J, Dumont AS, Jane JA Jr, Laws ER Jr (2005) Pediatric sellar tumors: diagnostic procedures and management. Neurosurg Focus 18:E6.
36. Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV et al (1994) Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 79:1135-1140. (Pubitemid 24342261)
37. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N et al (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524-529. (Pubitemid 44414278)
38. Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25:927-930. (Pubitemid 20073386)
39. Korevaar T, Wass J, Grossman A, Karavitaki N (2012) Disconnection hyperprolactinaemia in non-adenomatous sellar/parasellar lesions practically never exceeds 2000 mU/L. Clin Endocrinol (Oxf) 76:602-603.
40. Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C (1978) Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med 64:492-499. (Pubitemid 8302308)
41. Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK (2009) Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J Neuropathol Exp Neurol 68:482-488.
42. Martines V, Mansueto G, Tosi F, Caruso B, Castello R, Procacci C (2003) Selective venous sampling in diagnosing ACTH-dependent hypercortisolism. Radiol Med 105:356-361. (Pubitemid 37000428)
43. McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41:1133-1148.
44. Menucci M, Quiñones-Hinojosa A, Burger P, Salvatori R (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14:68-74.
45. Neggers SJ, van der Lely AJ (2011) Pegvisomant and improvement of quality of life in acromegalic patients. Horm Res Paediatr 76(Suppl. 1):102-105.
46. Nosé V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R et al (2011) Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 135:640-646.
47. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82-91.
48. Oldfield EH, Chrousos GP, Schulte HM, Schaaf M, McKeever PE, Krudy AG et al (1985) Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med 312:100-103. (Pubitemid 15192140)
49. Osamura RY, Egashira N, Kajiya H, Takei M, Tobita M, Miyakoshi T et al (2009) Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution. Acta Histochem Cytochem 29:95-104.
50. Pal A, Capatina C, Tenreiro AP, Guardiola PD, Byrne JV, Cudlip S et al (2011) Pituitary apoplexy in non-functioning pituitary adenomas: long term follow up is important because of significant numbers of tumour recurrences. Clin Endocrinol (Oxf) 75:501-504.
51. Puchner MJ, Lüdecke DK, Valdueza JM, Saeger W, Willig RP, Stalla GK, Odink RJ (1993) Cushing's disease in a child caused by a corticotropin- releasing hormone-secreting intrasellar gangliocytoma associated with an adrenocorticotropic hormone-secreting pituitary adenoma. Neurosurgery 33:920-924; discussion 924-925.
52. Puchner MJ, Lüdecke DK, Saeger W, Riedel M, Asa SL (1995) Gangliocytomas of the sellar region-a review. Exp Clin Endocrinol Diabetes 103:129-149.
53. Ranabir S, Baruah MP (2011) Pituitary apoplexy. Indian J Endocrinol Metab 15(Suppl. 3):S188-S196.
54. Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51:181-188. (Pubitemid 29378902)
55. Saeger W, Puchner MJ, Lüdecke DK (1994) Combined sellar gangliocytoma and pituitary adenoma in acromegaly or Cushing's disease. A report of 3 cases. Virchows Arch 425:93-99. (Pubitemid 24295513)
56. Salehi F, Doglietto F, Ridout R, Gentili F, Asa S, Zadeh G (2011) A case report and review of hyperprolactinemia that is not prolactinoma. Can J Neurol Sci 38:652-655.
57. Schulte HM, Oldfield EH, Allolio B, Katz DA, Berkman RA, Ali IU (1991) Clonal composition of pituitary adenomas in patients with Cushing's disease: determination by X-chromosome inactivation analysis. J Clin Endocrinol Metab 73:1302-1308. (Pubitemid 121000707)
58. Serri O, Berthelet F, Bélair M, Vallette S, Asa SL (2008) An unusual association of a sellar gangliocytoma with a prolactinoma. Pituitary 11:85-87. (Pubitemid 351168087)
59. Takino H, Herman V, Weiss M, Melmed S (1995) Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 80:1733-1738.
60. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ et al (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99-107. (Pubitemid 26002389)
61. Tischler AS (2008) Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 132:1272-1284.
62. Trouillas J, Sassolas G, Guigard MP, Fonlupt P, Ansaneli-Naves L, Perrin G (1996) Relationships between pathological diagnosis and clinical parameters in acromegaly. Metabolism 45:53-56.
63. Umeoka K, Sanno N, Osamura RY, Teramoto A (2002) Expression of GATA-2 in human pituitary adenomas. Mod Pathol 15:11-17. (Pubitemid 34081454)
64. Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, Scheithauer BW (2002) Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 15:1205-1212. (Pubitemid 35435139)
65. Wang EL, Qian ZR, Yamada S, Rahman MM, Inosita N, Kageji T et al (2009) Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol 20:209-220.
66. Wang H, Yu W, Zhang Z, Xu W, Zhang F, Bao W (2010) Ectopic pituitary adenoma in the spheno-orbital region. J Neuroophthalmol 30:135-137.